References
- Gallin JI , AllingDW, MalechHL et al. Itraconazole to prevent fungal infections in chronic granulomatous disease. N. Engl. J. Med. 348(24) , 2416–2422 (2003).
- Walsh TJ , AnaissieEJ, DenningDW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46(3) , 327–360 (2008).
- Pascual A , CalandraT, BolayS, BuclinT, BilleJ, MarchettiO. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis.46(2) , 201–211 (2008).
- Goldstein B , GiroirB, RandolphA. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr. Crit. Care Med.6(1) , 2–8 (2005).
- Smith J , SafdarN, KnasinskiV et al. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50(4) , 1570–1572 (2006).
- Andes D , PascualA, MarchettiO. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother.53(1) , 24–34 (2009).
- Okano M , YamadaM, OhtsuM et al. Successful treatment with methylprednisolone pulse therapy for a life-threatening pulmonary insufficiency in a patient with chronic granulomatous disease following pulmonary invasive aspergillosis and Burkholderia cepacia infection. Respiration 66(6) , 551–554 (1999).
- Eiden C , CociglioM, Hillaire-BuysD et al. Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring. Xenobiotica 40(10) , 701–706.
- Hassan A , BurhenneJ, RiedelKD et al. Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. Ther. Drug Monit. 33(1) , 86–93 (2011).
- Bourgeois S , LabudaD. Dynamic allele-specific oligonucleotide hybridization on solid support. Anal Biochem.324(2) , 309–311 (2004).
- Baldwin RM , OhlssonS, PedersenRS et al. Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br. J. Clin. Pharmacol. 65(5) , 767–774 (2008).
- Hulot JS , BuraA, VillardE et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 108(7) , 2244–2247 (2006).
- Yanni SB , AnnaertPQ, AugustijnsP, IbrahimJG, BenjaminDK Jr, Thakker DR. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab. Dispos.38(1) , 25–31 (2010).
- Weiss J , Ten Hoevel MM, Burhenne J et al.CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J. Clin. Pharmacol.49(2) , 196–204 (2009).
- Wang G , LeiHP, LiZ et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur. J. Clin. Pharmacol. 65(3) , 281–285 (2009).
- Li XQ , AnderssonTB, AhlstromM, WeidolfL. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab. Dispos.32(8) , 821–827 (2004).
- Carcillo JA , DoughtyL, KofosD et al. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure. Intensive Care Med. 29(6) , 980–984 (2003).
- Aitken AE , MorganET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab. Dispos.35(9) , 1687–1693 (2007).
- Chen Y , FergusonSS, NegishiM, GoldsteinJA. Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol. Pharmacol.64(2) , 316–324 (2003).
- Seger RA , GungorT, BelohradskyBH et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985–2000. Blood 100(13) , 4344–4350 (2002).